Amyloidosis
5 videos · last 6 months shuffled daily, then older videos newest first
▶
1:15 CARES Phase III Trials of Anselamimab in AL Amyloidosis
Giada Bianchi, MD, of Brigham and Women's Hospital and Dana-Farber discusses the Phase III CARES studies of anselamimab in newly diagnosed AL amyloidosis, which missed the primary endpoint but showed a mortality benefit in kappa disease, at SOHO 2026.
▶
11:25 HELIOS-B: Vutrisiran With and Without Tafamidis in ATTR-CM
Yasuhiro Hamatani, MD, PhD, discusses a HELIOS-B analysis in transthyretin amyloid cardiomyopathy finding vutrisiran's effects on mortality and cardiovascular events consistent in direction with or without baseline tafamidis, for JACC.
▶
13:58 Investigational Therapies and Clinical Trials for ATTR Amyloidosis
Sarah Cuddy, MD, MPH, of the Mass General Brigham Cardiac Amyloidosis Program, reviews the latest clinical trials of investigational therapies for patients with ATTR amyloidosis, for Amyloidosis Support Groups.
▶
2:45 ATTRibute-CM: Acoramidis Survival Over 54 Months
Kevin Alexander, MD, and C. Michael Gibson, MD, discuss interim findings from ATTRibute-CM and its open-label extension on survival with acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy, including p.V142I.
▶
8:13 Radcliffe Cardiology Looks at Results of the CRISPR-Cas9 First-in-Human Clinical Trial
A clinical trial of an investigational drug NTLA-2001 was tested recently in participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM), a type of serious heart disease.